Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

CBAY CymaBay Therapeutics

Watchlist
2.770
-0.180-6.10%
Close 07/01 16:00 ET
2.77000.00%
Post Mkt Price 07/01 16:02 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
2.980
Open
2.940
Turnover
1.09M
Low
2.765
Pre Close
2.950
Volume
387.31K
Market Cap
234.56M
P/E(TTM)
Loss
52wk High
4.740
Shares
84.68M
P/E(Static)
Loss
52wk Low
1.670
Float Cap
172.09M
Bid/Ask %
-42.86%
Historical High
15.590
Shs Float
62.12M
Volume Ratio
0.15
Historical Low
0.820
Dividend TTM
--
Div Yield TTM
900
P/B
2.18
Dividend LFY
--
Div Yield LFY
32490.97%
Turnover Ratio
0.62%
Amplitude
7.29%
Avg Price
2.821
Lot Size
1
Float Cap
172.09M
Bid/Ask %
-42.86%
Historical High
15.590
Shs Float
62.12M
Volume Ratio
0.15
Historical Low
0.820
Dividend TTM
--
P/B
2.18
Dividend LFY
--
Turnover Ratio
0.62%
Amplitude
7.29%
Avg Price
2.821
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
CEO: Shah, Sujal A.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top